The announcement was made by the CDMO’s CEO John Rim during a press conference at the event.
The $1.5 billion production plant is expected to have the shortest construction timeline of 24 months, made possible by the company’s “standardized design, accumulated operational excellence, and proven expertise”.
The new facility will add a capacity of 180,000 liters, and upon its completion, Samsung Biologics will maintain the world’s largest biomanufacturing capacity at 784,000 liters.
In July 2022, the company purchased 357,360m2 of land for the expansion, which will feature an Open Innovation Center for biotech incubation and four plants for a total capacity of 720,000 liters.
The news comes after the company recently completed its latest biomanufacturing plant, Plant 4, on June 1.
According to the CDMO, Plant 5’s completion reinforces its “unmatched speed and commitment to providing partners with high-quality services and products in response to the surging demand for biologics”.
John Rim, president and CEO of Samsung Biologics said: “Over a decade ago, we committed to bringing innovative solutions to our partners, and we’ve successfully delivered on that commitment with each new plant.”
“Now building on this foundation, Plant 5 will leverage our unparalleled experience and expertise to deliver long-term success for our clients. By expediting our capacity expansion and providing fully integrated services, we hope to close the gap between the demand and supply of life-saving biomedicines.”
Plant 5 will feature process integration and optimization, as well as advanced automation to deliver high productivity and quality throughout its operations.
“This strategic investment allows us to support our clients across the entire product lifecycle,” Rim added.
“Through innovation and sustainability, Bio Campus II will add unbeatable value to our existing services and offer expanded capacity in record time to enable their success.”